.jpg)
TORL BioTherapeutics, an emerging biopharmaceutical company, has recently made waves in the biotech industry. By successfully closing a $158 million Series B financing round, the company is poised to advance the development of its novel oncology biologics.
A Strategic Partnership with UCLA
TORL BioTherapeutics is founded on a strategic partnership with the Slamon Research Lab at UCLA, which has given the company exclusive development and commercial rights to biologics-based drug candidates focused on promising cancer targets.
The Slamon Research Lab: A Legacy of Innovation
The Slamon Research Lab, led by scientific co-founder Dennis Slamon, M.D., Ph.D., is renowned for its groundbreaking research in cancer treatment. Dr. Slamon's research has been instrumental in identifying HER2 as a target in breast cancer and the development and initial approval of trastuzumab (Herceptin).
Unraveling New Cancer Targets
Dr. Slamon's lab has also discovered CDK4/6 as an important target in hormone receptor (HR+) positive breast cancer. This has led to the clinical development of breakthrough therapies like palbociclib (Ibrance) and ribociclib (Kisqali), in HR+ breast cancer.
TORL's Pipeline: A Focus on Claudin 6 and Claudin 18.2
TORL's main drug programs target Claudin 6 (CLDN 6) and Claudin 18.2 (CLDN 18.2). Both targets are currently being evaluated in clinical trials.
Stepping up the Pace
TORL plans to put 2-3 additional compounds into clinical trials over the next 12 months. The company also aims to advance 1-2 new compounds each year.
A Unique Approach to Drug Discovery
TORL's approach to drug discovery and development is unique. The company leverages the Slamon research lab's discovery engine and validation platforms to promote its novel oncology biologics.
Capital Efficient and Rapid Development
TORL's innovative approach has allowed it to move forward three internally developed drug programs into the clinic and advance two more through IND-enabling studies, all with less than $50 million.
A Strong Foundation for Future Growth
With the closing of the Series B financing, TORL is poised to advance its new programs into the clinic and existing clinical-stage programs into the next phase.
Addressing a Global Health Challenge
Despite significant advances in cancer diagnosis and treatment, the disease continues to pose a major health challenge worldwide. TORL is committed to addressing this through the discovery, development, and commercialization of first and best-in-class antibody-based immunotherapies.
TORL's Team: A Blend of Scientific Expertise and Industry Experience
TORL is built on a 30-year history of scientific collaboration amongst a team of clinical pioneers and laboratory researchers. The scientific founding team is accompanied by a board of directors and scientific advisors who bring a wealth of industry experience and expertise.
A Unique Model for Company Formation
TORL's partnership with the Slamon research lab and UCLA allows it to leverage decades of scientific expertise and deep research capabilities. This unique model avoids the significant costs and risks associated with early-stage discovery, giving TORL a competitive edge.
Looking Ahead: A Bright Future for TORL and Oncology Biologics
TORL's promising drug candidates, TORL-1-23 and TORL-2-307, represent potential therapies for ovarian and gastric cancers, two indications with significant unmet patient need. With strong investor support, TORL is well-positioned to advance these lead programs toward late-stage clinical trials.
Expanding the Horizons of Cancer Therapy
With its unique model and innovative approach, TORL is set to make significant contributions to cancer therapy. As it continues to build on its legacy of innovation, the company is well on its way to fulfilling its mission of transforming the lives of cancer patients.
About TORL BioTherapeutics: TORL BioTherapeutics LLC is a clinical-stage biopharmaceutical company focused on developing novel, antibody-based therapeutics to transform the lives of cancer patients. The company is headquartered in Los Angeles.
Source: TORL Biotherapeutics
Comments